Footnotes
Data sharing: The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
https://www.ahajournals.org/journal/circDominick J. Angiolillo, MD, PhD, University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL 32209. Email dominick.angiolillo@jax.ufl.edu
References
- 1.Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome.Circulation. 2011; 123:798–813. doi: 10.1161/CIRCULATIONAHA.109.913376LinkGoogle Scholar
- 2.Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome.Nat Rev Cardiol. 2015; 12:30–47. doi: 10.1038/nrcardio.2014.156CrossrefMedlineGoogle Scholar
- 3.Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, et al.. Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 Trial.J Am Coll Cardiol. 2016; 67:1145–1154. doi: 10.1016/j.jacc.2015.12.062CrossrefMedlineGoogle Scholar
- 4.Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, et al.; THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes.N Engl J Med. 2019; 381:1309–1320. doi: 10.1056/NEJMoa1908077CrossrefMedlineGoogle Scholar
- 5.Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, et al.; THEMIS Steering Committee and Investigators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.Lancet. 2019; 394:1169–1180. doi: 10.1016/S0140-6736(19)31887-2CrossrefMedlineGoogle Scholar